Examines scholarisine I's effect on lysosomal function in cancer cells, suggesting a new therapeutic avenue.
Scholarisine A ( 1 ) represents a structurally distinct and synthetically intriguing subfamily of the echitamine/akuammiline-type alkaloids. Inspired by its postulated biogenetic logic, we developed a radical cyclization strategy that retains the key bond-forming site while replacing the aldol reaction. This reaction-altering biomimetic strategy, combined with expeditious preparation of a tetracyclic precursor, enabled a 13-step, scalable synthesis of 1 . Moreover, facile access to its congeners, scholarisines I, T, and W ( 2 – 4 ), was achieved. Compound 2 impairs lysosomal degradative capacity and thus inhibits late-stage autophagy in cancer cells.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: